Jeffrey M. Lipton, MD, PhD, holds a BA from Queens College, City University of New York. He received a PhD in chemistry from Syracuse University and his medical degree magna cum laude from Saint Louis University Medical School. He did his pediatric training at the Children’s Hospital, Boston, MA, and his pediatric hematology/oncology fellowship training at the Children’s Hospital and the Dana Farber (formerly Sidney Farber) Cancer Institute in Boston.
As the president of the American Society of Pediatric Hematology Oncology (ASPHO) from 2010 to 2012, one of his priorities was the development of mentoring and career development opportunities for members. He also has mentored medical students and summer college students.
Dr. Lipton currently serves as a K08 advisor to Jason Farrar, MD, who has completed his fellowship at Johns Hopkins and is now assistant professor of pediatrics at the University of Arkansas. As an MD, PhD and principal investigator of an R01 supporting the Diamond Blackfan Anemia Registry, Dr. Lipton is responsible for directing translation research that relies upon robust communication between laboratory and clinical scientists.
Dr. Lipton is also the chief of hematology/oncology and stem cell transplantation at the Steven and Alexandra Cohen Children’s Medical Center of New York in New Hyde Park; the center head of patient oriented research at The Feinstein Institutes for Medical Research; professor at Feinstein’s Elmezzi Graduate School of Molecular Medicine; and a professor of pediatrics and molecular medicine at the Zucker School of Medicine.
Dr. Lipton’s research interests focus on the rare inherited bone marrow failure syndromes. His current work is devoted to understanding the genetics, cellular and molecular biology of Diamond Blackfan anemia (DBA) and particularly malignant predisposition and birth defects observed in patients with DBA. He is the recipient of the 2010 Saint Louis University’s School of Medicine Alumni Merit Award and is an author of 175 original articles, reviews and book chapters.
The major goal of Dr. Lipton’s research is the elucidation of the genetics and pathophysiology of Diamond Blackfan anemia (DBA). During his career, he has attempted to translate laboratory knowledge into relevant diagnostic and therapeutic tools. The group he currently leads is working with numerous collaborators to develop meaningful genotype-phenotype correlations. This “group science” has led to the discovery of a number of DBA genotypes.
Through the Diamond Blackfan Anemia Registry (DBAR), opened in 1991, Dr. Lipton’s team has been able to provide a valuable substrate for laboratory investigations. In addition, they have developed mouse embryonic stem cell lines haploinsufficient for both rpl5 and rps19 that exhibit very different characteristics with regard to erythroid differentiation. In summary, the availability of animal models and a robust DBA database of well-characterized patients provide the cornerstone for advances in the diagnosis and treatment of DBA. Thus, translating knowledge from animal models to human disease is a natural progression of this work.
Dr. Lipton’s group has referred patients from the United States, Canada and abroad with undiagnosed bone marrow failure syndromes for diagnostic evaluation. Many of these patients remain undiagnosed and likely represent “new” disorders. Some of them have intermittent hematopoietic failure and are of great interest for Dr. Lionel Blanc’s studies.
Johnson Liu, MD
Abena Appiah-Kubi, MD
Lionel Blanc, PhD
Clinical Research Unit:
Adrianna Vlachos, MD
Associate Investigator, Head
Eva Atsidaftos, MA
Research Associate, CCRA
Ellen Muir, MSN
Queens College, City University of New York
Field of study: Chemistry
Syracuse University, Syracuse New York
Field of study: Physical Chemistry
St. Louis University Medical School, St. Louis, MO
Degree: MD magna cum laude
Field of study: Medicine